# Bifidobacterium bifidum BGN4 DSM 20082

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/bifidobacterium-bifidum-bgn4-dsm-20082
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-25
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** Bifidobacterium bifidum BGN4 DSM 20082, B. bifidum BGN4, BGN4 strain, DSM 20082, Bifidobacterium bifidum BGN4, B. bifidum DSM 20082

## Overview

Bifidobacterium bifidum BGN4 (DSM 20082) is a clinically studied probiotic strain that exerts anti-inflammatory effects by suppressing [pro-inflammatory cytokine](/ingredients/condition/inflammation)s including IL-6, IL-1β, and TNF-α while reinforcing intestinal tight junction proteins such as occludin and claudin. Its primary mechanisms involve modulation of the NF-κB signaling pathway and enhancement of host [antioxidant](/ingredients/condition/antioxidant) enzyme activity, contributing to improved [gut barrier](/ingredients/condition/gut-health) integrity and digestive comfort.

## Health Benefits

• Reduces intestinal [inflammation](/ingredients/condition/inflammation) by suppressing cytokines (IL-6, IL-1β, TNF-α) and protecting tight junctions - shown in multiple animal models
• Improves abdominal pain and defecation discomfort in digestive disorders - supported by one human RCT (n=70)
• Enhances [antioxidant](/ingredients/condition/antioxidant) defenses by boosting SOD, GSH-Px, and CAT enzyme activity - demonstrated in colitis models
• Supports [cognitive function](/ingredients/condition/cognitive) and reduces neuroinflammation - shown in Alzheimer's disease mouse models when combined with B. longum
• Strengthens [intestinal barrier integrity](/ingredients/condition/gut-health) and reduces gut dysbiosis - evidenced in paraprobiotic form studies

## Mechanism of Action

B. bifidum BGN4 downregulates the NF-κB signaling pathway, directly reducing transcription of [pro-inflammatory cytokine](/ingredients/condition/inflammation)s IL-6, IL-1β, and TNF-α in intestinal epithelial and immune cells. The strain also upregulates tight junction proteins—occludin, claudin-1, and ZO-1—stabilizing paracellular permeability and reducing endotoxin translocation across the gut epithelium. Additionally, BGN4 stimulates host antioxidant enzymes including superoxide dismutase (SOD) and catalase, reducing [reactive oxygen species](/ingredients/condition/antioxidant) accumulation in colonic tissue.

## Clinical Summary

The primary human evidence for BGN4 comes from one randomized controlled trial (n=70) in adults with functional digestive disorders, where supplementation significantly improved abdominal pain scores and defecation discomfort compared to placebo. Animal model studies using colitis-induced rodents have consistently demonstrated reduced mucosal IL-6, IL-1β, and TNF-α levels alongside preserved tight junction architecture. [Antioxidant](/ingredients/condition/antioxidant) benefits, including elevated SOD and catalase activity, have been documented in preclinical models but await confirmation in human trials. Overall, the evidence base is promising but limited for extrapolation to broader populations, as large-scale human RCTs remain scarce.

## Nutritional Profile

Bifidobacterium bifidum BGN4 DSM 20082 is a probiotic microorganism, not a conventional food ingredient, so its nutritional contribution is characterized by cellular components and bioactive metabolites rather than traditional macronutrients. Each viable cell contributes microbial biomass composed primarily of protein (~50-60% of dry cell weight, including surface-layer proteins and adhesins), lipoteichoic acids, and peptidoglycan cell wall components. Key bioactive compounds include: exopolysaccharides (EPS) produced during fermentation which act as [prebiotic](/ingredients/condition/gut-health)s and [immunomodulat](/ingredients/condition/immune-support)ors; short-chain fatty acids (SCFAs) — primarily acetate and lactate as primary fermentation end-products, with acetate typically produced at 1-3 mM range in gut models; B-group vitamins synthesized during [metabolism](/ingredients/condition/weight-management), particularly folate (B9) and riboflavin (B2) in trace quantities (micrograms per 10^9 CFU); and bacteriocin-like inhibitory substances (BLIS) that contribute to colonization resistance. The strain produces β-galactosidase enzyme, aiding lactose digestion. Cell wall lipopolysaccharide-free structure (Gram-positive) reduces endotoxin load. Bioavailability is CFU-dependent — effective doses in studied contexts range from 1×10^8 to 5×10^9 CFU/day; viability is significantly reduced by gastric acid (pH <3) without encapsulation, with estimated 10-40% survival to distal ileum under standard delivery conditions. No meaningful caloric, fat, carbohydrate, or mineral contribution at typical supplemental doses.

## Dosage & Preparation

No clinically studied human dosages are specified in the research. Animal models used 0.3% w/w BGN4 in diet for 4 weeks, while the human RCT duration was 8 weeks but exact CFU dosage was not reported. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

B. bifidum BGN4 is generally regarded as safe for healthy adults, with reported side effects limited to mild and transient gastrointestinal symptoms such as bloating or increased flatulence during the initial days of supplementation. Individuals who are severely immunocompromised, have central venous catheters, or are recovering from major surgery should consult a physician before use, as [probiotic](/ingredients/condition/gut-health) bacteremia, though exceedingly rare, has been reported with Bifidobacterium species in such populations. No clinically significant drug interactions have been formally established, though concurrent antibiotic use may reduce the viability of live organisms and diminish efficacy. Safety data in pregnant and breastfeeding women specifically for the BGN4 strain are limited, and use during pregnancy should be discussed with a healthcare provider.

## Scientific Research

Human clinical evidence is limited to one RCT (n=70) showing significant reduction in abdominal pain and defecation discomfort after 8 weeks. Most evidence comes from preclinical studies including DSS-induced colitis models (PMIDs: 17218154, 35148194) and an Alzheimer's disease mouse model (PMID: 34421576). No human meta-analyses or multiple RCTs specifically on this strain were identified.

## Historical & Cultural Context

No evidence of traditional use in historical medicine systems was found. BGN4 DSM 20082 emerged as a commercial [probiotic](/ingredients/condition/gut-health) strain since 2000, lacking traditional medicine context.

## Synergistic Combinations

Bifidobacterium longum BORI, Lactobacillus species, [Prebiotic](/ingredients/condition/gut-health) fibers, [Glutathione](/ingredients/condition/detox), Vitamin D

## Frequently Asked Questions

### What is Bifidobacterium bifidum BGN4 and how is it different from other probiotics?

B. bifidum BGN4 (deposited as DSM 20082) is a specific, characterized probiotic strain isolated and studied for its targeted anti-inflammatory and gut-barrier-protective properties. Unlike generic Bifidobacterium bifidum strains, BGN4 has documented strain-specific activity against NF-κB-driven cytokine production—particularly IL-6, IL-1β, and TNF-α—and has been tested in at least one human RCT, distinguishing it from many commercially used strains with only preclinical data.

### What dose of Bifidobacterium bifidum BGN4 was used in clinical studies?

The human RCT investigating BGN4 in functional digestive disorders used a supplementation protocol with a defined colony-forming unit (CFU) dose over a set intervention period, though publicly available summaries of this trial report outcomes primarily in terms of symptom scores rather than detailing the exact CFU count per serving. Typical probiotic research doses for Bifidobacterium strains range from 1×10⁹ to 1×10¹⁰ CFU per day, and consumers should check product labeling for BGN4-specific dosing to ensure alignment with studied amounts.

### Can Bifidobacterium bifidum BGN4 help with IBS or irritable bowel syndrome?

The one human RCT conducted with BGN4 enrolled adults experiencing abdominal pain and defecation discomfort consistent with functional digestive complaints, and participants showed statistically significant improvements in these symptoms versus placebo. While these findings are relevant to IBS-like presentations, the trial was not specifically labeled as an IBS study using formal Rome diagnostic criteria, so direct claims for IBS require cautious interpretation until confirmatory trials in formally diagnosed IBS populations are completed.

### How does Bifidobacterium bifidum BGN4 reduce intestinal inflammation?

BGN4 reduces intestinal inflammation primarily by inhibiting the NF-κB signaling cascade within gut epithelial and immune cells, which lowers gene expression of the pro-inflammatory cytokines IL-6, IL-1β, and TNF-α. Simultaneously, the strain stabilizes tight junction proteins—including occludin and claudin-1—preventing bacterial endotoxins like lipopolysaccharide (LPS) from crossing the intestinal epithelium and triggering systemic immune activation, a process that itself perpetuates inflammation.

### Is Bifidobacterium bifidum BGN4 safe to take long-term?

Based on available data, BGN4 appears well-tolerated in healthy adult populations, with no serious adverse events reported in published studies and side effects largely confined to mild, transient bloating during the first week of use. Long-term safety studies specifically for BGN4 beyond the duration of existing trials are not yet published, so individuals with immunosuppression, inflammatory bowel disease requiring medical management, or those on immunosuppressant drugs such as corticosteroids or biologics should seek physician guidance before extended use.

### Does Bifidobacterium bifidum BGN4 DSM 20082 interact with antibiotics or other medications?

Bifidobacterium bifidum BGN4 is generally considered safe to use alongside most medications, though timing of administration relative to antibiotics is important since antibiotics can reduce probiotic viability. It is advisable to take this strain at least 2–3 hours apart from antibiotic doses to maximize survival and colonization. Consult with a healthcare provider if taking immunosuppressant medications, as probiotics may modulate immune function.

### Is Bifidobacterium bifidum BGN4 DSM 20082 safe for children and during pregnancy?

Bifidobacterium bifidum BGN4 is a non-pathogenic strain with a long history of safe use in infant formulas and pediatric populations, making it suitable for children when dosed appropriately. Safety during pregnancy has not been extensively studied in clinical trials, so consultation with an obstetrician is recommended before supplementation. The strain is naturally part of the human microbiome and has no known teratogenic effects.

### What clinical evidence supports Bifidobacterium bifidum BGN4 DSM 20082 for gut-brain health?

While Bifidobacterium bifidum BGN4 has demonstrated cognitive function support in preclinical studies, direct human clinical evidence for psychobiotic effects remains limited. The strain's ability to reduce intestinal inflammation and modulate cytokines suggests a potential gut-brain axis mechanism, but rigorous randomized controlled trials in humans are needed to establish clinical efficacy for neurological conditions. Current evidence is strongest for gastrointestinal and inflammatory outcomes rather than mental health applications.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*